Eli Lilly And Company (LLY): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Eli Lilly and Company ( LLY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.5%. By the end of trading, Eli Lilly and Company rose $0.67 (1.3%) to $50.63 on light volume. Throughout the day, 3,818,874 shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 6,301,300 shares. The stock ranged in a price between $50.25-$50.68 after having opened the day at $50.34 as compared to the previous trading day's close of $49.96. Other companies within the Health Care sector that increased today were: Tonix Pharmaceuticals ( TNXP), up 30.6%, Auxilium Pharmaceuticals ( AUXL), up 11.9%, Puma Biotechnology ( PBYI), up 11.7% and Cormedix ( CRMD), up 11.4%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $56.2 billion and is part of the drugs industry. The company has a P/E ratio of 11.4, below the S&P 500 P/E ratio of 17.7. Shares are up 1.3% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 2 analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Mast Therapeutics ( MSTX), down 41.5%, Uroplasty ( UPI), down 9.7%, Idenix Pharmaceuticals ( IDIX), down 8.5% and Dehaier Medical Systems ( DHRM), down 7.5% , were all laggards within the health care sector with Ariad Pharmaceuticals ( ARIA) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief